文献速递骨质疏松与代谢性骨病

加拿大靶向骨密度检测优化骨折预防

Targeted bone density testing for optimizing fracture prevention in Canada.
PubMed 文献 · Osteoporos Int · 2020-02-12

研究基于加拿大曼尼托巴省骨密度注册数据,分析50岁以上无既往低创伤骨折或高风险药物使用的女性和男性,评估不检测骨密度(BMD)的加拿大FRAX®工具识别符合药物治疗阈值(基于BMD计算的FRAX®主要骨质疏松性骨折风险MOF≥20%)的敏感性。结果显示不检测BMD的FRAX MOF临床评分>10%对识别符合治疗条件者具有高敏感性(女性99.3%,男性99.1%),且简单年龄规则(无额外临床风险因素时70岁,有则65岁)敏感性相似。

要点

  • 不检测BMD的FRAX MOF临床评分>10%可高敏感性识别符合加拿大治疗阈值者。
  • 年龄规则:无额外风险因素70岁、有则65岁检测BMD,敏感性女性99.9%、男性>99.9%。
  • 基于BMD的FRAX MOF≥20%阈值下,4.3%女性和0.7%男性符合治疗条件。

核心结论

  • 不检测BMD的FRAX工具能有效识别符合加拿大当前基于BMD的FRAX治疗阈值(MOF≥20%)的个体。
  • 可通过简单年龄切点(无额外临床风险因素70岁,有则65岁)实施初始BMD检测。

研究设计与样本

  • 研究基于加拿大曼尼托巴省骨密度注册数据,纳入50岁以上无既往低创伤骨折或高风险药物使用的女性和男性。
  • 样本包括50,700名女性(平均年龄65.5±9.4岁)和4152名男性(平均年龄69.2±10.0岁)。
  • 使用加拿大FRAX®工具分别计算不检测BMD(MOF-clinical)和检测BMD(MOF-BMD)的骨折概率。

主要发现

  • FRAX MOF-clinical评分>10%者在女性中占33.8%,男性中占13.3%(P<0.001)。
  • 女性MOF-clinical达到10%的中位年龄(IQR)在无额外FRAX临床风险因素时为70岁(69-72),有额外风险因素时为65岁(62-67)。
  • 男性MOF-clinical达到10%的中位年龄(IQR)在无额外风险因素时为83岁(82-86),有额外风险因素时为76岁(70-78)。
  • 以MOF-BMD≥20%为干预阈值,4.3%女性和0.7%男性符合治疗条件。
  • MOF-clinical>10%识别符合治疗条件者的敏感性为女性99.3%、男性99.1%;年龄规则敏感性为女性99.9%、男性>99.9%。

关键数值与推荐

  • 药物治疗干预阈值:基于BMD计算的FRAX®主要骨质疏松性骨折风险(MOF)≥20%。
  • 初始BMD检测指征年龄规则:无额外FRAX临床风险因素时70岁,有一个或多个临床风险因素时65岁。
  • MOF-clinical>10%作为高敏感性识别符合治疗条件者的cutoff(女性敏感性99.3%,男性99.1%)。

临床怎么用

  • 在加拿大平均风险人群中,可先使用不检测BMD的FRAX评估,MOF-clinical>10%者建议进一步BMD检测以确定是否达到治疗阈值。
  • 可依据年龄规则(无额外风险因素70岁,有则65岁)启动初始BMD检测,以优化骨折预防。

局限性

  • 研究基于加拿大曼尼托巴省注册数据,结果外推需谨慎。
  • 仅纳入50岁以上无既往低创伤骨折或高风险药物使用的平均风险人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The Canadian FRAX® tool used without bone mineral density (BMD) is highly sensitive for identifying individuals qualifying for pharmacotherapy based upon an intervention threshold of 20% for major osteoporotic fracture risk (MOF) computed with BMD. INTRODUCTION: This analysis was performed to inform initial BMD testing as part of Osteoporosis Canada's Guidelines Update for women and men at average risk, assuming a pharmacotherapy intervention threshold of 20% for FRAX® MOF computed with BMD. METHODS: Women and men age 50 + without previous low-trauma fracture or high-risk medication use were identified in a BMD registry for the province of Manitoba, Canada. Fracture probability assessments with the Canadian FRAX® tool were computed without and with BMD (denoted MOF-clinical and MOF-BMD, respectively). RESULTS: The study population consisted of 50,700 women (mean age 65.5 ± 9.4 years) and 4152 men (69.2 ± 10.0 years). FRAX MOF-clinical score was > 10% in 33.8% of women and 13.3% of men (P < 0.001). The median (interquartile range [IQR]) age for MOF-clinical to reach 10% in women was 70 (69-72) and 65 years (62-67) years in the absence and presence of additional FRAX clinical risk factors, respectively. In men, comparable ages were 83 years [82-86] and 76 [70-78] years. Using MOF-BMD of 20% as the intervention threshold, 4.3% of women and 0.7% of men qualified for treatment. MOF-clinical > 10% had high sensitivity to identify those qualifying for treatment (99.3% in women and 99.1% in men). An age-based rule ("BMD testing is indicated at age 70 if no additional FRAX clinical risk factors are present, or at age 65 if one or more clinical risk factors exists") gave similarly high sensitivity (women 99.9% and men > 99.9%). CONCLUSIONS: FRAX without BMD offers an effective strategy to identify individuals meeting the current Canadian treatment threshold based upon FRAX® with BMD (≥ 20%). Moreover, this can be operationalized using simple age cutoffs of 70 years in the absence of additional clinical risk factors and 65 years in the presence of additional clinical risk factors.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Leslie WD, Morin SN, Lix LM, et al. Targeted bone density testing for optimizing fracture prevention in Canada. Osteoporos Int. 2020. PMID: 32052071. doi:10.1007/s00198-020-05335-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。